Sharescart Research Club logo

Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹3 Cr.
Stock P/E
1.3
P/B
0.1
Current Price
₹2.4
Book Value
₹ 20.1
Face Value
10
52W High
52W Low
Dividend Yield
0%

Oceanaa Biotek Overview

Business

Oceanaa Biotek Industries Ltd. is an Indian company primarily engaged in the aquaculture sector. Its core business model revolves around integrated shrimp farming, encompassing hatchery operations, shrimp feed production, and the cultivation of various shrimp species. The company also processes shrimp and develops value-added seafood products. It makes money by selling farmed shrimp and shrimp-related products to domestic and international markets.

Revenue Mix

The company's primary revenue streams are derived from its aquaculture operations, particularly the farming and processing of shrimp. While specific revenue contributions by segment are not consistently detailed publicly, its activities span:

Shrimp Hatchery (producing shrimp seeds/post-larvae)

Shrimp Farming (cultivation of Vannamei and other species)

Shrimp Feed Manufacturing

Processing and Export of Farmed Shrimp

Industry

The Indian aquaculture industry is a significant global player, particularly in shrimp production and export, benefiting from extensive coastline and suitable climate. It is characterized by a mix of large integrated players and numerous smaller farmers. Oceanaa Biotek Industries Ltd. operates as an integrated player within this industry, aiming for efficiency across its value chain from hatchery to processing. Its positioning likely emphasizes quality, biosecurity, and potentially sustainable practices to cater to both domestic and international demand, competing with other established shrimp exporters in India.

MOAT

Oceanaa Biotek's competitive advantages, if any, likely stem from:

Integrated Operations: Control over the entire value chain from hatchery to feed and processing can lead to cost efficiencies, quality control, and reduced reliance on external suppliers.

Biosecurity & Disease Management: Expertise in preventing and managing common aquaculture diseases, which are a major risk in the industry.

Scale and Technology: Investment in modern farming techniques and processing infrastructure can improve yields and product quality.

Market Access: Established relationships with domestic and international buyers for its seafood products.

Growth Drivers

Key factors that can drive growth for Oceanaa Biotek over the next 3-5 years include:

Rising Global Seafood Consumption: Increasing demand for protein-rich, healthy food sources, particularly shrimp.

Expanding Export Markets: India's competitive position in the global shrimp market continues to drive export opportunities.

Technological Advancements: Adoption of advanced farming techniques (e.g., biofloc, recirculation aquaculture systems) to improve yields and sustainability.

Value-Added Products: Focus on processing and producing higher-margin value-added shrimp products.

Government Support: Favorable policies and subsidies for aquaculture development in India.

Risks

Key business risks include:

Disease Outbreaks: Vulnerability to diseases like White Spot Syndrome (WSSV) in shrimp, which can devastate harvests.

Environmental & Climate Risks: Impact of extreme weather events, water quality degradation, and climate change on farming operations.

Feed Price Volatility: Fluctuations in raw material prices for shrimp feed can impact profitability.

Regulatory Changes: Evolving environmental norms, export policies, and food safety standards can impose compliance costs.

Market Price Fluctuations: Global shrimp prices are subject to supply-demand dynamics, impacting revenue and margins.

Competition: Intense competition from other domestic and international shrimp producers.

Management & Ownership

Oceanaa Biotek Industries Ltd. is promoted by individuals with experience in the aquaculture sector. Typically, Indian companies have strong promoter groups who hold significant ownership stakes and often lead the management team. The quality of management would depend on their track record in navigating industry challenges, executing expansion plans, and maintaining financial health. Ownership structure generally involves a substantial promoter holding, with the remainder held by public shareholders.

Outlook

Oceanaa Biotek operates in a dynamic sector with significant growth potential, driven by robust global demand for seafood. Its integrated business model offers some resilience against market fluctuations and potential for efficiency. However, the company faces inherent risks such as disease outbreaks, climate change impacts, and price volatility, which are common to the aquaculture industry. Success will depend on its ability to leverage technological advancements, maintain stringent biosecurity, manage operational costs effectively, and expand its market reach while navigating the inherent environmental and market challenges.

Oceanaa Biotek Share Price

Live · BSE · Inception: 2005
| |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Oceanaa Biotek Quarterly Results

#(Fig in Cr.) Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020
Net Sales 14 8 3 5 5 3 13 5 4 1
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 14 8 3 5 5 3 13 5 4 1
Total Expenditure 11 7 27 3 3 2 13 3 3 2
Operating Profit 3 1 -24 2 2 1 -0 2 1 -1
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 0 1 1 1 1 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 2 0 -24 1 1 1 -1 1 0 -1
Provision for Tax 1 0 0 -0 0 -0 0 0 0 -0
Profit After Tax 2 0 -24 1 1 1 -1 1 0 -1
Adjustments -0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 2 0 -24 1 1 1 -1 1 0 -1
Adjusted Earnings Per Share 1.2 0.1 -17.5 0.9 1 0.8 -1 0.9 0.1 -1.1

Oceanaa Biotek Profit & Loss

#(Fig in Cr.) Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 TTM
Net Sales 0 0 0 7 46 32 36 60 36 26 23
Other Income 0 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 7 46 32 36 61 36 26 23
Total Expenditure 0 0 0 6 44 27 31 39 54 21 21
Operating Profit -0 -0 0 1 2 5 5 21 -18 5 2
Interest 0 0 0 0 0 0 0 1 0 0 0
Depreciation 0 0 0 0 1 1 1 3 3 2 1
Exceptional Income / Expenses 0 0 0 -0 -0 -0 0 0 0 0 0
Profit Before Tax -0 -0 0 1 1 4 4 17 -21 2 -1
Provision for Tax 0 0 0 0 0 1 2 6 -1 0 0
Profit After Tax -0 -0 0 0 1 2 3 11 -20 2 -1
Adjustments 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments -0 -0 0 0 1 2 3 11 -20 2 -1
Adjusted Earnings Per Share -12.4 -8.4 0.1 0.4 0.8 2.1 2.7 8.1 -14.8 1.6 -1.1

Oceanaa Biotek Balance Sheet

#(Fig in Cr.) Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Shareholder's Funds -0 -0 3 6 10 12 15 45 25 27
Minority's Interest 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 1 1 1
Other Non-Current Liabilities 0 0 0 -0 0 -0 0 1 0 0
Total Current Liabilities 0 0 0 4 3 7 7 13 13 12
Total Liabilities 0 0 3 10 13 19 22 60 39 41
Fixed Assets 0 0 0 0 7 7 6 24 17 21
Other Non-Current Assets 0 0 0 0 0 0 0 0 0 0
Total Current Assets 0 0 3 10 6 13 17 36 23 20
Total Assets 0 0 3 10 13 19 22 60 39 41

Oceanaa Biotek Cash Flow

#(Fig in Cr.) Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Opening Cash & Cash Equivalents 0 0 0 0 2 0 0 0 0 0
Cash Flow from Operating Activities 0 0 0 -0 2 1 1 2 -5 7
Cash Flow from Investing Activities 0 0 0 0 -8 -1 -0 -22 5 -6
Cash Flow from Financing Activities 0 0 0 2 4 -0 -0 20 -0 -0
Net Cash Inflow / Outflow 0 0 0 2 -2 0 -0 0 -0 0
Closing Cash & Cash Equivalent 0 0 0 2 0 0 0 0 0 0

Oceanaa Biotek Ratios

# Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Earnings Per Share (Rs) -12.45 -8.44 0.05 0.39 0.79 2.13 2.7 8.06 -14.78 1.63
CEPS(Rs) -12.45 -8.44 0.05 0.4 1.4 3.45 3.78 10.62 -12.94 3.23
DPS(Rs) 0 0 0 0 0 0.35 0.6 1.5 0 0
Book NAV/Share(Rs) -49.51 -45.11 5.77 6.21 10.02 11.73 14.8 33.35 18.62 20.26
Core EBITDA Margin(%) 0 -111.59 12.19 11.16 4.54 15.98 14.7 34.77 -49.33 18.45
EBIT Margin(%) 0 -111.59 12.19 8.68 2.85 11.35 11.8 29.16 -56.22 10.11
Pre Tax Margin(%) 0 -116.66 12.18 8.59 2.73 11 11.71 27.97 -56.68 9.71
PAT Margin (%) 0 -143.53 8.36 5.19 1.74 6.78 7.49 18.09 -55.27 8.64
Cash Profit Margin (%) 0 -143.53 8.36 5.3 3.08 10.95 10.5 23.82 -48.37 17.07
ROA(%) -63.4 -96.04 1.71 5.35 6.98 13.28 13.19 26.44 -40.26 5.53
ROE(%) 0 0 1.91 8.12 10.25 19.62 20.32 36.25 -56.88 8.41
ROCE(%) 0 0 2.76 13.58 16.7 32.59 31.89 57.2 -56.03 9.52
Receivable days 0 0 6.16 114.98 36.54 43.33 36.82 47.33 107.81 112.91
Inventory Days 0 0 184.11 0 0 53.68 47.93 34.2 35.01 9.19
Payable days 0 0 67.93 132.29 28.02 74.62 81.13 48.75 41.72 127.72
PER(x) 0 0 0 0 7.51 5.38 18.55 18.85 0 3.86
Price/Book(x) 0 0 0 0 0.59 0.98 3.38 4.56 1.3 0.31
Dividend Yield(%) 0 0 0 0 0 3.07 1.2 0.99 0 0
EV/Net Sales(x) 0 0.45 8.83 0.46 0.13 0.35 1.39 3.42 0.93 0.36
EV/Core EBITDA(x) -0.42 -0.4 72.45 4.12 2.9 2.22 9.32 9.81 -1.89 1.92
Net Sales Growth(%) 0 0 3300 1872.31 592.64 -30.82 13.43 65.83 -39.98 -29.29
EBIT Growth(%) -4131.82 47.26 471.54 1304.33 127.26 175.64 18.78 306.96 -215.7 112.73
PAT Growth(%) 0 32.18 298 1124.48 131.8 169.92 26.3 297.73 -283.36 111.06
EPS Growth(%) 0 32.18 100.64 631.24 101.59 169.92 26.3 199.06 -283.36 111.06
Debt/Equity(x) 0 0 0 0 0.01 0.01 0 0.03 0.04 0.03
Current Ratio(x) 0.01 0.11 12.86 2.31 1.88 1.68 2.33 2.75 1.75 1.6
Quick Ratio(x) 0.01 0.11 12.19 2.31 1.88 1.05 1.64 2.26 1.71 1.54
Interest Cover(x) -3778.41 -22.04 743.02 96.19 23.44 32.07 121.65 24.52 -121.91 25.05
Total Debt/Mcap(x) 0 0 0 0 0.02 0.01 0 0.01 0.03 0.09

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -28% -10% -11%
Operating Profit CAGR 0% +20%
PAT CAGR -13% +15%
Share Price CAGR 0% -32% -19% -18%
ROE Average +8% -4% +6% +5%
ROCE Average +10% +4% +15% +11%

Oceanaa Biotek Shareholding Pattern

Latest · Dec 2020
100% held
Promoters 39.09 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 60.91 %
# Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020
Promoter 39.0739.0739.0739.0739.0739.0939.0939.0939.0939.09
FII 0.02000000000
DII 000000.030000
Public 60.9360.9360.9360.9360.9360.9160.9160.9160.9160.91
Others 0000000000
Total 100100100100100100100100100100

Oceanaa Biotek Peer Comparison

Aquaculture Edit Columns

Oceanaa Biotek Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Oceanaa Biotek Pros & Cons

Pros

  • Stock is trading at 0.1 times its book value
  • Company is almost debt free.

Cons

  • Promoter holding is low: 39.09%.
  • Company has a low return on equity of -4% over the last 3 years.
  • Debtor days have increased from 41.72 to 127.72days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp